These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7605858)

  • 1. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn's disease.
    Van Ierssel AJ; Van der Sluys Veer A; Verspaget HW; Griffioen G; Van Hogezand RA; Lamers CB
    Aliment Pharmacol Ther; 1995 Apr; 9(2):173-8. PubMed ID: 7605858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease.
    van Ierssel GJ; van der Sluys Veer A; Verspaget HW; Griffioen G; van Hogezand RA; Lamers CB
    Immunopharmacology; 1995 Feb; 29(1):11-7. PubMed ID: 7768667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cortisol and ACTH on corticosteroid-suppressed peripheral blood natural killer cells from healthy volunteers and patients with Crohn's disease.
    van Ierssel GJ; Mieremet-Ooms MA; van der Zon AM; van Hogezand RA; Wagtmans MJ; van der Sluys Veer A; Lamers CB; Verspaget HW
    Immunopharmacology; 1996 Sep; 34(2-3):97-104. PubMed ID: 8886853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide in the management of patients with Crohn's disease.
    Thomson AB; Sadowski D; Jenkins R; Wild G
    Can J Gastroenterol; 1997 Apr; 11(3):255-60. PubMed ID: 9167034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral budesonide in active Crohn's disease.
    Löfberg R; Danielsson A; Salde L
    Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of intestinal mucosal natural killer cells by corticosteroids.
    Van Ierssel AJ; Mieremet-Ooms MA; Van der Zon JM; Van Hogezand RA; Griffioen G; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 1997 Apr; 11(2):347-53. PubMed ID: 9146774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
    Escher JC;
    Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
    Löfberg R; Rutgeerts P; Malchow H; Lamers C; Danielsson A; Olaison G; Jewell D; Ostergaard Thomsen O; Lorenz-Meyer H; Goebell H; Hodgson H; Persson T; Seidegård C
    Gut; 1996 Jul; 39(1):82-6. PubMed ID: 8881815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide or prednisolone in active Crohn's disease.
    Baert F; Rutgeerts P
    Ann Med; 1995 Dec; 27(6):631. PubMed ID: 8652141
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease.
    Brogan M; Hiserodt J; Oliver M; Stevens R; Korelitz B; Targan S
    J Clin Immunol; 1985 May; 5(3):204-11. PubMed ID: 3874211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
    Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled-release budesonide in Crohn's disease.
    Drug Ther Bull; 1997 Apr; 35(4):30-1. PubMed ID: 9282408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.